Autonomic Dysfunction

Categories: Blood diseases, Neuronal diseases

Aliases & Classifications for Autonomic Dysfunction

MalaCards integrated aliases for Autonomic Dysfunction:

Name: Autonomic Dysfunction 53
Autonomic Nervous System Disorders 71
Autonomic Disorder 54


External Ids:

UMLS 71 C1145628

Summaries for Autonomic Dysfunction

NINDS : 53 Dysautonomia refers to a disorder of autonomic nervous system (ANS) function that generally involves failure of the sympathetic or parasympathetic components of the ANS, but dysautonomia involving excessive or overactive ANS actions also can occur. Dysautonomia can be local, as in reflex sympathetic dystrophy, or generalized, as in pure autonomic failure. It can be acute and reversible, as in Guillain-Barre syndrome, or chronic and progressive. Several common conditions such as diabetes and alcoholism can include dysautonomia. Dysautonomia also can occur as a primary condition or in association with degenerative neurological diseases such as Parkinson's disease. Other diseases with generalized, primary dysautonomia include multiple system atrophy and familial dysautonomia. Hallmarks of generalized dysautonomia due to sympathetic failure are impotence (in men) and a fall in blood pressure during standing (orthostatic hypotension). Excessive sympathetic activity can present as hypertension or a rapid pulse rate.

MalaCards based summary : Autonomic Dysfunction, also known as autonomic nervous system disorders, is related to multiple system atrophy 1 and neuropathy, hereditary sensory and autonomic, type iib, and has symptoms including seizures, tremor and constipation. An important gene associated with Autonomic Dysfunction is ECE1 (Endothelin Converting Enzyme 1), and among its related pathways/superpathways are Neuroscience and Sympathetic Nerve Pathway (Neuroeffector Junction). The drugs Diphenhydramine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and spinal cord, and related phenotypes are behavior/neurological and integument

Wikipedia : 74 Dysautonomia or autonomic dysfunction is a condition in which the autonomic nervous system (ANS) does... more...

Related Diseases for Autonomic Dysfunction

Diseases related to Autonomic Dysfunction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 635)
# Related Disease Score Top Affiliating Genes
1 multiple system atrophy 1 32.1 SNCA DBH
2 neuropathy, hereditary sensory and autonomic, type iib 31.7 SCN9A RETREG1
3 neuropathy, hereditary sensory and autonomic, type ic 31.1 SPTLC2 SPTLC1
4 neuropathy, hereditary sensory and autonomic, type ia 31.1 SPTLC2 SPTLC1
5 pure autonomic failure 31.1 SNCA DBH
6 neuropathy, hereditary sensory and autonomic, type iia 30.2 SPTLC2 SPTLC1 SCN9A RETREG1
7 neuropathy, hereditary sensory and autonomic, type iii 29.9 SPTLC1 DBH
8 central hypoventilation syndrome, congenital 29.6 ECE1 DBH
9 sensory peripheral neuropathy 29.6 SPTLC1 RETREG1
10 autonomic neuropathy 29.5 SPTLC2 SPTLC1 SCN9A RETREG1
11 movement disease 29.4 SNCA SLC18A2
12 neuropathy 29.3 SPTLC2 SPTLC1 SCN9A RETREG1
13 alcohol dependence 29.2 SNCA SLC18A2 DBH
14 alzheimer disease 28.0 SPTLC2 SPTLC1 SNCA ECE1 DBH
15 charcot-marie-tooth disease 27.5 SPTLC2 SPTLC1 SNCA SCN9A RETREG1
16 hirschsprung disease, cardiac defects, and autonomic dysfunction 12.8
17 pitt-hopkins syndrome 11.8
18 neuroleptic malignant syndrome 11.7
19 autosomal dominant leukodystrophy with autonomic disease 11.7
20 dysautonomia 11.5
21 lambert-eaton myasthenic syndrome 11.5
22 autonomic nervous system disease 11.4
23 spinocerebellar ataxia 34 11.3
24 spastic paraplegia 2, x-linked 11.3
25 neuronal intranuclear inclusion disease 11.3
26 parkinsonism-dystonia, infantile, 2 11.3
27 paroxysmal extreme pain disorder 11.1
28 perry syndrome 11.1
29 indifference to pain, congenital, autosomal recessive 11.1
30 parkinson disease 4, autosomal dominant 11.1
31 aromatic l-amino acid decarboxylase deficiency 11.1
32 sudden infant death with dysgenesis of the testes syndrome 11.1
33 parkinson disease 5, autosomal dominant 11.1
34 brown-vialetto-van laere syndrome 11.1
35 striatonigral degeneration 11.1
36 brain dopamine-serotonin vesicular transport disease 11.1
37 opsoclonus-myoclonus syndrome 11.1
38 myoclonic encephalopathy of infants 11.1
39 syncope 10.5
40 orthostatic intolerance 10.5
41 guillain-barre syndrome 10.4
42 polyneuropathy 10.4
43 multiple sclerosis 10.4
44 constipation 10.4
45 resting heart rate, variation in 10.4
46 impotence 10.4
47 cardiac conduction defect 10.3
48 sleep apnea 10.3
49 peripheral nervous system disease 10.3
50 migraine with or without aura 1 10.3

Graphical network of the top 20 diseases related to Autonomic Dysfunction:

Diseases related to Autonomic Dysfunction

Symptoms & Phenotypes for Autonomic Dysfunction

UMLS symptoms related to Autonomic Dysfunction:

seizures, tremor, constipation, vomiting, back pain, pain, headache, diarrhea, syncope, mydriasis, chronic pain, sciatica, vertigo/dizziness, sleeplessness, rectal tenesmus, increased sweating, decrease in appetite, vomiting alone, rectal pain, dry throat, hyperemesis, anal pain, vomiting in newborn, lightheadedness, warm skin, palpitations - fluttering, pounding heart, syncope, effort, blackout - symptom

MGI Mouse Phenotypes related to Autonomic Dysfunction:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 DBH RETREG1 SCN9A SLC18A2 SNCA SPTLC1
2 integument MP:0010771 9.73 DBH ECE1 RETREG1 SCN9A SNCA SPTLC2
3 mortality/aging MP:0010768 9.7 DBH ECE1 SCN9A SLC18A2 SNCA SPTLC1
4 nervous system MP:0003631 9.5 DBH ECE1 RETREG1 SCN9A SLC18A2 SNCA
5 taste/olfaction MP:0005394 8.8 SCN9A SLC18A2 SNCA

Drugs & Therapeutics for Autonomic Dysfunction

Drugs for Autonomic Dysfunction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Zolpidem Approved Phase 4 82626-48-0 5732
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Metronidazole Approved Phase 4 443-48-1 4173
Norepinephrine Approved Phase 4 51-41-2 439260
Droxidopa Approved, Investigational Phase 4 23651-95-8 443940
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
Mecamylamine Approved, Investigational Phase 4 60-40-2 4032
12 Dopamine Antagonists Phase 4
13 Tranquilizing Agents Phase 4
14 Hypnotics and Sedatives Phase 4
15 GABA Agents Phase 4
16 GABA Agonists Phase 4
17 GABA-A Receptor Agonists Phase 4
18 Dopamine agonists Phase 4
19 Anti-Arrhythmia Agents Phase 4
20 Anti-Bacterial Agents Phase 4
21 Anti-Infective Agents Phase 4
22 Antiparasitic Agents Phase 4
23 Antiprotozoal Agents Phase 4
24 Antiemetics Phase 4
25 Gastrointestinal Agents Phase 4
26 Pharmaceutical Solutions Phase 4
27 Antiparkinson Agents Phase 4
28 Serotonin Agents Phase 4
29 Serotonin Antagonists Phase 4
30 Cholinergic Agents Phase 4
31 Cholinergic Antagonists Phase 4
32 Hypoglycemic Agents Phase 4
33 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
34 Sodium-Glucose Transporter 2 Inhibitors Phase 4
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
Levodopa Approved Phase 3 59-92-7 6047
Methyldopa Approved Phase 3 555-30-6 38853
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
Carbidopa Approved Phase 3 28860-95-9 34359
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284
Deferasirox Approved, Investigational Phase 3 201530-41-8 5493381
44 Sympathomimetics Phase 3
45 Dopamine Agents Phase 3
46 Duloxetine Hydrochloride Phase 2, Phase 3
47 Parasympatholytics Phase 2, Phase 3
48 Serotonin and Noradrenaline Reuptake Inhibitors Phase 2, Phase 3
49 Muscarinic Antagonists Phase 2, Phase 3
50 Dopamine D2 Receptor Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 221)
# Name Status NCT ID Phase Drugs
1 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
2 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
3 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
4 Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
5 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
6 The Study of Heart Rate Variability in Patients With Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
7 Efectividad de Saccharomyces Oulardii Para Reducir Los síntomas Gastrointestinales y Evitar el Sobrecrecimiento Bacteriano en Esclerosis sistémica Completed NCT03692299 Phase 4 Saccharomyces Boulardii Oral Tablet;Metronidazole
8 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
9 Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients Recruiting NCT03091881 Phase 4 Granisetron 0.1 MG/ML;Placebos
10 Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis Recruiting NCT03914677 Phase 4 Mecamylamine Oral Tablet
11 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Not yet recruiting NCT04193566 Phase 4 Forxiga
12 Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
13 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT02427464 Phase 3
14 Effects of Escitalopram vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control Completed NCT00215228 Phase 2, Phase 3 duloxetine vs. escitalopram
15 An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension Completed NCT00738062 Phase 3 Droxidopa;Placebo
16 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00782340 Phase 3 Placebo;Droxidopa
17 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00633880 Phase 3 Placebo;Droxidopa
18 Gut Microbiota Alteration and Improvement of Ataxia in Patients of Multiple System Atrophy Treating With Tllsh2910 - a Randomized, Placebo-controlled, Double-blinded, Cross-over, Single-center Clinical Trial Recruiting NCT03901638 Phase 3 Tllsh2910;Placebo
19 Treatment of Hypotensive Patients Having a Unique Pattern of Autonomic Symptoms Enrolling by invitation NCT00581477 Phase 3 droxidopa;placebo;alpha-methyldopa;carbidopa;metyrosine;levodopa;atomoxetine;metoclopramide
20 Mechanisms, Safety and Efficacy of Optimising Pacemaker Heart Rate for Contractility: Effects on Walk Time, Cardiac Remodelling and Quality of Life Not yet recruiting NCT04201015 Phase 2, Phase 3
21 Clinical Importance of Treating Iron Overload in Sickle Cell Disease Terminated NCT00981370 Phase 3 deferasirox
22 Evaluation à Six Mois du système de dénervation rénale Chez Les Patients Atteints d'Insuffisance Cardiaque Unknown status NCT02471729 Phase 1, Phase 2
23 The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy Unknown status NCT00281502 Phase 2 Rifaximin (drug)
24 A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome Completed NCT01703533 Phase 2 NNZ-2566;Placebo
25 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins Completed NCT00750867 Phase 2 intravenous immunoglobulin (IVIg)
26 A Phase I/II, Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Patients With Painful Diabetic Peripheral Neuropathy Completed NCT01002235 Phase 1, Phase 2
27 A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome Completed NCT02715115 Phase 2 NNZ-2566;Placebo
28 Daily Incorporation of Blueberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension. Completed NCT01686282 Phase 2
29 A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT01475786 Phase 2
30 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Three Doses of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Completed NCT00229437 Phase 2 TAK-128;TAK-128;TAK-128;Placebo
31 Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure? Completed NCT00291720 Phase 2 Spironolactone;Placebo
32 A Phase 1 Clinical Study to Assess Safety and Efficacy of Oral Fingolimod (FTY720) in Children With Rett Syndrome. Completed NCT02061137 Phase 1, Phase 2 fingolimod (FTY720)
33 A Phase II, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Clinical Benefit and Safety of Droxidopa in Patients With Intradialytic Hypotension Completed NCT00657046 Phase 2 Droxidopa;Placebo
34 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying Completed NCT01602549 Phase 2 GSK962040 (25 mg tablet);Placebo
35 Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease Completed NCT03865121 Phase 2 Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)
36 Effects of Oral L-citrulline/L-arginine in Watermelon on Central Blood Pressure and Arterial Stiffness in Individuals With Obesity-related High Blood Pressure Completed NCT01185041 Phase 1, Phase 2
37 Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome Completed NCT01607073 Phase 2 Verapamil
38 A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease Completed NCT02818777 Phase 2 cannabidiol
39 Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. Recruiting NCT03137537 Phase 2 Ivabradine;Placebo Oral Tablet
40 The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes Recruiting NCT03426085 Phase 2 Liraglutide 6 mg Solution for Injection
41 A Double-Blind, Randomized, Placebo-Controlled Trial To Evaluate The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Recruiting NCT02915263 Phase 2 IGIV-C;0.9% Sodium Chloride
42 Left Cardiac Sympathetic Denervation (LCSD) for Cardiomyopathy Feasibility Pilot Study Recruiting NCT03071653 Phase 2
43 A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease Recruiting NCT03582137 Phase 2 Cannabidiol
44 The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease Recruiting NCT03775096 Phase 2 Carvedilol
45 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Active, not recruiting NCT02458690 Phase 2 Antidepressant Medications
46 Inflammation Inhibition for Microvascular and Autonomic Dysfunction in Obese Prediabetic Humans Active, not recruiting NCT01977417 Phase 2 Salsalate;Placebo
47 Controlled Trial of 3,4-Diaminopyridine in LEMS Terminated NCT02090725 Phase 2 3-4 Diaminopyridine
48 The Role of the "Inflammatory/ Pathogen Burden" for Cardiac Ageing Terminated NCT01045512 Phase 2 fluvastatin
49 An Open-Label, Multi-Center Study to Evaluate the Safety of Long-Term Administration of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Terminated NCT00756041 Phase 2 TAK-128
50 Vagal Stimulation in POTS - The Autonomic Inflammatory Reflex (Pilot 3) Recruiting NCT03124355 Phase 1 placebo sugar pill;Pyridostigmine Pill;Galantamine Pill

Search NIH Clinical Center for Autonomic Dysfunction

Genetic Tests for Autonomic Dysfunction

Anatomical Context for Autonomic Dysfunction

MalaCards organs/tissues related to Autonomic Dysfunction:

Heart, Testes, Spinal Cord, Brain, Liver, Skin, Kidney

Publications for Autonomic Dysfunction

Articles related to Autonomic Dysfunction:

(show top 50) (show all 5808)
# Title Authors PMID Year
FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models. 61
31751571 2020
Craniofacial Autonomic Dysfunction in Migraine: Implications for Treatment and Prognosis. 61
31895071 2020
Preoperative Blood Pressure Complexity Indices as a Marker for Frailty in Patients Undergoing Cardiac Surgery. 61
31668744 2020
Effects of postexercise cooling on heart rate recovery in normotensive and hypertensive men. 61
31769592 2020
Can body mass index identify cardiac autonomic dysfunction in women who are apparently healthy? 61
31096889 2020
Isolated Insular Stroke: Clinical Presentation. 61
32023607 2020
Bladder Autonomic Dysfunction after a Parietal Stroke. 61
32033903 2020
Lesion Configuration Effect on Stroke-Related Cardiac Autonomic Dysfunction. 61
32035088 2020
Orthostatic heart rate does not predict symptomatic burden in pediatric patients with chronic orthostatic intolerance. 61
31385108 2020
The Orthostatic Discriminant and Severity Scale (ODSS): an assessment of orthostatic intolerance. 61
30604164 2020
Chronic metformin reduces systemic and local inflammatory proteins and improves hypertension-related cardiac autonomic dysfunction. 61
31653514 2020
Postoperative Atrial Fibrillation Following Cardiac Surgery: From Pathogenesis to Potential Therapies. 61
31502217 2020
Sweating Disorders. 61
31996625 2020
Cardiovascular complications and its relationship with functional outcomes in Guillain-Barré syndrome. 61
31504947 2020
Association Between Systemic Inflammation, Carotid Arteriosclerosis, and Autonomic Dysfunction. 61
31093927 2020
Alcohol-induced autonomic dysfunction: a systematic review. 61
31222483 2020
Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment. 61
31809788 2020
First-Ever Ischemic Stroke and Incident Major Adverse Cardiovascular Events in 93 627 Older Women and Men. 61
31914883 2020
Management of Orthostatic Hypotension. 61
31996627 2020
Letter to the Editor: Re: "Is heart rate variability a valuable method to investigate cardiac autonomic dysfunction in subjects with leukemia? A systematic review to evaluate its importance in clinical practice" by Kirizawa et al. 61
31659446 2020
Cardiac autonomic tone, plasma BDNF levels and paroxetine response in newly diagnosed patients of generalised anxiety disorder. 61
32022607 2020
Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment - the ComOn-study. 61
32028945 2020
The hemodynamic and pain impact of peripheral nerve block versus spinal anesthesia in diabetic patients undergoing diabetic foot surgery. 61
29196938 2020
Autonomic History, Examination, and Laboratory Evaluation. 61
31996620 2020
Kinetics of α-synuclein prions preceding neuropathological inclusions in multiple system atrophy. 61
32017806 2020
Phenotypic variability and its pathological basis in amyotrophic lateral sclerosis. 61
31802540 2020
Long-term cardiac arrhythmia and chronotropic evaluation in patients with severe anorexia nervosa (LACE-AN): A pilot study. 61
31917489 2020
Cognition in multiple system atrophy: a single-center cohort study. 61
32031752 2020
New evidence on the management of Lewy body dementia. 61
31519472 2020
Prediabetes, diabetes, metabolic syndrome and small fiber neuropathy. 61
32012301 2020
Complex Regional Pain Syndrome Evolving to Full-Blown Fibromyalgia: A Proposal of Common Mechanisms. 61
32028304 2020
Geometry of the Poincaré plot can segregate the two arms of autonomic nervous system - A hypothesis. 61
32014816 2020
Preliminary Evidence That Resting State Heart Rate Variability Predicts Reactivity to Tactile Stimuli in Rett Syndrome. 61
31552776 2020
Dysautonomia as the Presenting Symptom in Anti-Muscle-Specific Kinase Antibody Myasthenia Gravis. 61
31868676 2020
Renin angiotensin system molecules and nitric oxide local interactions in the adrenal gland of Trypanosoma cruzi infected rats. 61
31788770 2020
Lessons of the month 3: Duodenal perforation after polystyrene sulfonate. 61
31941743 2020
Anti-NMDA Receptor Encephalitis, Vaccination and Virus. 61
31820697 2020
Exercise alters cerebellar and cortical activity related to working memory in phenotypes of Gulf War Illness. 61
32025659 2020
Persistent instability in a nonhomogeneous delay differential equation system of the Valsalva maneuver. 61
31785229 2020
Endothelial and Autonomic Dysfunction at Early Stages of Glucose Intolerance and in Metabolic Syndrome. 61
31529423 2020
White matter alteration and autonomic impairment in obstructive sleep apnea. 61
31992402 2020
Diverse cognitive impairment after spinal cord injury is associated with orthostatic hypotension symptom burden. 61
31738949 2020
Reduced heart rate variability predicts fatigue severity in individuals with chronic fatigue syndrome/myalgic encephalomyelitis. 61
31906988 2020
Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. 61
31971444 2020
Limbic encephalitis associated with AMPA receptor and CRMP5 antibodies: A case report and literature review. 61
31991060 2020
Small vessel disease pathological changes in neurodegenerative and vascular dementias concomitant with autonomic dysfunction. 61
31357238 2020
State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson's disease. 61
31957505 2020
Stroke Outcome Prediction by Blood Pressure Variability, Heart Rate Variability, and Baroreflex Sensitivity. 61
31964286 2020
Alterations in heart rate variability are associated with abnormal myocardial perfusion. 61
32024598 2020
Effects of Heart Rate Variability Biofeedback in Patients With Acute Ischemic Stroke: A Randomized Controlled Trial. 61
31635477 2020

Variations for Autonomic Dysfunction

Expression for Autonomic Dysfunction

Search GEO for disease gene expression data for Autonomic Dysfunction.

Pathways for Autonomic Dysfunction

Pathways related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.87 SNCA SCN9A DBH
2 10.32 SLC18A2 DBH
Show member pathways
9.98 SLC18A2 DBH

GO Terms for Autonomic Dysfunction

Cellular components related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.8 SPTLC2 SPTLC1 SLC18A2 SCN9A RETREG1 ECE1
2 membrane GO:0016020 9.56 SPTLC2 SPTLC1 SNCA SLC18A2 SCN9A RETREG1
3 synaptic vesicle membrane GO:0030672 9.32 SNCA SLC18A2
4 terminal bouton GO:0043195 9.16 SNCA SLC18A2
5 serine C-palmitoyltransferase complex GO:0017059 8.62 SPTLC2 SPTLC1

Biological processes related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.61 SNCA SLC18A2 DBH
2 locomotory behavior GO:0007626 9.54 SLC18A2 DBH
3 post-embryonic development GO:0009791 9.52 SLC18A2 SCN9A
4 sensory perception of pain GO:0019233 9.51 SCN9A RETREG1
5 sphingolipid biosynthetic process GO:0030148 9.49 SPTLC2 SPTLC1
6 sphingolipid metabolic process GO:0006665 9.48 SPTLC2 SPTLC1
7 biosynthetic process GO:0009058 9.46 SPTLC2 SPTLC1
8 response to amphetamine GO:0001975 9.4 SLC18A2 DBH
9 ceramide biosynthetic process GO:0046513 9.37 SPTLC2 SPTLC1
10 positive regulation of receptor recycling GO:0001921 9.32 SNCA ECE1
11 sphingosine biosynthetic process GO:0046512 9.26 SPTLC2 SPTLC1
12 sphingomyelin biosynthetic process GO:0006686 9.16 SPTLC2 SPTLC1
13 positive regulation of lipophagy GO:1904504 8.96 SPTLC2 SPTLC1
14 sphinganine biosynthetic process GO:0046511 8.62 SPTLC2 SPTLC1

Molecular functions related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 9.16 SNCA DBH
2 pyridoxal phosphate binding GO:0030170 8.96 SPTLC2 SPTLC1
3 serine C-palmitoyltransferase activity GO:0004758 8.62 SPTLC2 SPTLC1

Sources for Autonomic Dysfunction

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....